Cramer's 'Mad Money' Recap: Once Hated, Now Loved
NEW YORK (TheStreet) -- Investors are like most TV watchers, always changing channels, Jim Cramer told his "Mad Money" TV show viewers Thursday. He opined about a multitude of stocks that were once hated but are now loved as investors have once again changed their minds.
No stock illustrates this move better than Facebook
Other sectors that are getting a second look include travel, thanks to TripAdvisor
Biotech remains a hot sector, with Cramer recommending Celgene
Other Cramer faves include the autos, banks and oil and gas stocks, along with some technology and semiconductor names. Cramer even had kind words for Starbucks
Executive Decision: Tarek Sherif
In the "Executive Decision" segment, Cramer spoke with Tarek Sherif, founder, chairman and CEO of Medidata Solutions
Sherif said the Food and Drug Administration is mandating that the industry change the way it performs clinical trials, and Medidata is the prime beneficiary of that mandate. He said by using modern cloud technology, Medidata is driving value by improving the quality of trials with less risk and helping to bring better drugs to market faster.
Sherif said clinical trials are still largely in the early stages of using technology, but those that have embraced the technology are getting through their trials faster. He said Medidata has a terrific business model where 80% to 90% of its revenue stems from repeat customers.